Status:
ENROLLING_BY_INVITATION
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Lead Sponsor:
Wren Laboratories LLC
Conditions:
Neuroendocrine Tumor
Carcinoid
Eligibility:
All Genders
18+ years
Brief Summary
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems. Treatment options include surgery, medical and ablative therapies as ...
Detailed Description
Background: Survival for neuroendocrine tumors is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. Non-invasive biomarkers have been...
Eligibility Criteria
Inclusion
- Gastroenteropancreatic neuroendocrine tumor
- Bronchopulmonary neuroendocrine tumor
- Gastroenteropancreatic neuroendocrine carcinoma
- Pre- and post-surgical patients
- Watch \& Wait/no treatment
- Treatment including somatostatin analogues, PRRT, targeted therapies.
- Patient provides informed consent
Exclusion
- N/A
Key Trial Info
Start Date :
February 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT02270567
Start Date
February 1 2015
End Date
December 1 2030
Last Update
November 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wren Laboratories
Branford, Connecticut, United States, 06405